Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0016 USD
Change Today 0.00 / 0.00%
Volume 16.7M
BHRT On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

bioheart inc (BHRT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/10/14 - $0.03
52 Week Low
10/9/15 - $0.0010
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOHEART INC (BHRT)

Related News

No related news articles were found.

bioheart inc (BHRT) Related Businessweek News

No Related Businessweek News Found

bioheart inc (BHRT) Details

Bioheart, Inc. focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases. The company’s clinical development pipeline includes MyoCell and MyoCell SDF-1, which are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for improving cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of lower limb ischemia and rheumatoid arthritis. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and sells cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

4 Employees
Last Reported Date: 08/3/15
Founded in 1999

bioheart inc (BHRT) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $1.3M
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $671.3K
Compensation as of Fiscal Year 2014.

bioheart inc (BHRT) Key Developments

Bioheart, Inc. Reports Earnings Results for the Year 2014

Bioheart, Inc. reported earnings results for the year 2014. For the year, the company reported 2,040% increase in year over year revenues to $2.1 million in 2014 from $0.1 million in 2013. Net loss was $2.25 million against $3.14 million a year ago. Cash used in operating activities was $1.1 million against $1.9 million a year ago.

Bioheart, Inc., Special/Extraordinary Shareholders Meeting, Feb 02, 2015

Bioheart, Inc., Special/Extraordinary Shareholders Meeting, Feb 02, 2015., at 09:00 US Eastern Standard Time. Location: 13794 NW 4 Street. Agenda: To elect seven directors of the company; to ratify the appointment of Fiondella, Milone, and LaSaracina LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015; to approve the 2013 Omnibus Equity Compensation Plan; to consider and, if deemed advisable, approve an advisory vote on executive compensation; to consider an advisory vote determining the frequency of future executive compensation advisory votes; and to transact such other business as may properly come before the Meeting.

Bioheart, Inc. Announces Positive 12 Month Preliminary Data From Phase I Angel Trial

Bioheart, Inc. released the preliminary 12 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). At the 12 month time point, patients are demonstrating a statistically significant average improvement in ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3 percentage points in EF. The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10 percentage points (p=0.01) and at the 12 month follow up patients showed this same level of improvement (p=0.01). This phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells (AdipoCell(TM)) in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHRT:US $0.00 USD 0.00

BHRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Capricor Therapeutics Inc $4.46 USD -0.0399
Cesca Therapeutics Inc $0.60 USD -0.001
International Stem Cell Corp $3.90 USD 0.00
Nuo Therapeutics Inc $0.06 USD -0.014
StemCells Inc $0.44 USD +0.0383
View Industry Companies

Industry Analysis


Industry Average

Valuation BHRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHEART INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at